Transcutaneous Acupoint Electrical Stimulation and Postoperative Delirium Delirium

NCT06318351 | Recruiting DMC

• 1 other identifier: TJ-IRB202402015
• Study Type: observational
• Target: 476
• Locations: 1 country
• Sites: 2

Brief Summary

Investigating postoperative delirium in patients undergoing thoracoscopic lung resection surgery who have received or not received relevant transcutaneous acupoint electrical stimulation treatment preoperatively, observing postoperative recovery quality indicators, evaluating the necessity of treatment, and clarifying the potential mechanisms by which transcutaneous acupoint electrical stimulation may improve postoperative delirium.

Conditions

Delirium, Postoperative

Keywords

Delirium; Thoracoscopic lung resection surgery

Outcome Measures

Primary Outcomes (1)

• Delirium

  Mini-Mental State Examination, MMSE

  7days

Secondary Outcomes (1)

• Recovery

  7days

Study Arms (1)

Transcutaneous Electrical Acupoint Stimulation

The effect of Transcutaneous Electrical Acupoint Stimulation on postoperative vision was observed according to anesthesiologist's habit of using or not using it.

Procedure: transcutaneous acupoint electrical stimulation

Interventions

transcutaneous acupoint electrical stimulation PROCEDURE

This is a safe and non-invasive procedure, similar to an electrode sheet, which applies a weak current to a specific site to achieve the purpose of acupoint stimulation.

Transcutaneous Electrical Acupoint Stimulation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients undergoing thoracoscopic pneumonectomy

You may qualify if:

• Voluntary participation in the study;
• Age ≥ 18 years;
• Patients scheduled for thoracoscopic lung resection surgery;
• ASA grade I-III.

You may not qualify if:

• History of severe central nervous system diseases, psychiatric disorders, cognitive impairment, intellectual disability, or Mini-Mental State Examination (MMSE) score ≤23;
• History of opioid addiction, long-term use of analgesic drugs, or psychotropic drugs;
• Severe cardiovascular and cerebrovascular diseases;
• Severe liver and kidney dysfunction: Child-Pugh grade B, C patients, patients requiring regular dialysis, etc.;
• Pregnant or postpartum women;
• Patients with language communication barriers;
• Deemed unsuitable for participation by the researchers.

Sponsors & Collaborators

• Qin Zhang: lead
• National Natural Science Foundation of China: collaborator

Study Sites (2)

Guangdong Hospital of Traditional Chinese Medicine

Guangzhou, Guangdong, 510000, China

NOT YET RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma

MeSH Terms

Conditions

Emergence Delirium; Delirium

Condition Hierarchy (Ancestors)

Confusion; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Neurocognitive Disorders; Mental Disorders

Study Officials

• Qin Zhang, phd

  Tongji Medical College, Huazhong University of Science and Technology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xiao Ran, phd

CONTACT

15926207366; ranxiao1001@tjh.tjmu.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 7 Days
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 12, 2024
• First Posted: March 19, 2024
• Study Start: February 1, 2024
• Primary Completion: December 30, 2024
• Study Completion: August 30, 2025
• Last Updated: April 9, 2024

Record last verified: 2024-04

Locations

CN (2)